June 19, 2018

BLINCYTO is the First-and-Only Approved Bispecific CD19-Directed CD3 T Cell Engager (BiTE®) Immunotherapy

Amgen Receives European Commission Approval To Add Overall Survival Data To BLINCYTO® (blinatumomab) Label